MedTrace Logo

Tau PET Imaging in Atypical Dementias

NCT03283449 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2025-04-06

No results posted yet for this study

Summary

The goal of this study is to demonstrate the feasibility of mapping tau pathology in subjects with Primary Progressive Aphasia, using PET protocol with F-AV-1451 (trade name AV-1451) and to systematically document the extent and location of tau pathology in PPA patients in vivo using the same techniques.

Conditions

  • Primary Progressive Aphasia With Suspected Alzheimer's Disease

Interventions

DRUG

18F-AV-1451

DEVICE

PET

PET scanner for brain imaging

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • University of Chicago

    lead OTHER

Principal Investigators

  • Emily Rogalski, Ph.D. · University of Chicago

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2025-02-28
Completion
2025-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03283449 on ClinicalTrials.gov